Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Synthetic microparticles conjugated with VEGF165 improve the survival of endothelial progenitor cells via microRNA-17 inhibition

Synthetic microparticles conjugated with VEGF165 improve the survival of endothelial progenitor cells via microRNA-17 inhibition

Thumbnail Image
Download
Name

s41467-017-00746-7.pdf

Size

2.07 MB

Format

Adobe PDF

Checksum (MD5)

3ce96dd63af0e2f4a09e00a0f9a155cd

Download all files submitted through automated deposit
sword-2018-04-27.original.zip (1.36 MB)
Author(s)
Zoldan, Janet
•
Besnier, Marie
•
Carreto, Laura
•
Saif, Jaimy
•
Fernandes, Rui
•
Santos, Tiago
•
Bernardino, Liliana
•
Emanueli, Costanza
•
Ferreira, Lino
•
Aday, Sezin
more
Date Issued
September 2017
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Aday, Sezin et al. “Synthetic Microparticles Conjugated with VEGF165 Improve the Survival of Endothelial Progenitor Cells via microRNA-17 Inhibition.” Nature Communications 8, 1 (September 2017): 747 © 2017 The Author(s)
Version
Final published version
Abstract
Several cell-based therapies are under pre-clinical and clinical evaluation for the treatment of ischemic diseases. Poor survival and vascular engraftment rates of transplanted cells force them to work mainly via time-limited paracrine actions. Although several approaches, including the use of soluble vascular endothelial growth factor (sVEGF) - VEGF 165 , have been developed in the last 10 years to enhance cell survival, they showed limited efficacy. Here, we report a pro-survival approach based on VEGF-immobilized microparticles (VEGF-MPs). VEGF-MPs prolong VEGFR-2 and Akt phosphorylation in cord blood-derived late outgrowth endothelial progenitor cells (OEPCs). In vivo, OEPC aggregates containing VEGF-MPs show higher survival than those treated with sVEGF. Additionally, VEGF-MPs decrease miR-17 expression in OEPCs, thus increasing the expression of its target genes CDKN1A and ZNF652. The therapeutic effect of OEPCs is improved in vivo by inhibiting miR-17. Overall, our data show an experimental approach to improve therapeutic efficacy of proangiogenic cells for the treatment of ischemic diseases.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Attribution 4.0 International (CC BY 4.0)
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/115214
DOI of Published Version
https://doi.org/10.1038/S41467-017-00746-7
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.